

Instance: composition-en-18d76b54ce97b530a72d79629f6d8b0a
InstanceOf: CompositionUvEpi
Title: "Composition for ucedane Package Leaflet"
Description:  "Composition for ucedane Package Leaflet"
Usage: #example

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mock)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - ucedane"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Ucedane is and what it is used for  </li>
<li>What you need to know before you take Ucedane </li>
<li>How to take Ucedane  </li>
<li>Possible side effects  </li>
<li>How to store Ucedane  </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What ucedane is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What ucedane is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Ucedane can help eliminating excessive ammonia plasma levels (elevated ammonia level in 
the blood). Ammonia is especially toxic for the brain and leads, in severe cases, to reduced 
levels of consciousness and to coma. 
Hyperammonaemia may be due to<br />
* the lack of a specific liver enzyme N-acetylglutamate synthase. Patients with this rare 
disorder are not able to eliminate nitrogen waste, which builds up after eating protein. 
This disorder persists during the entire life of the affected patient and therefore the 
need for this treatment is lifelong. 
* isovaleric acidaemia, methylmalonic acidaemia or propionic acidaemia. Patients suffering 
from one of these disorders need treatment during the hyperammonaemia crisis. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take ucedane"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take ucedane"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Ucedane 
if you are allergic to carglumic acid or any of the other ingredients of Ucedane (listed in section 6). 
Do not take Ucedane during breast-feeding. </p>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before taking Ucedane. </p>
<p>Ucedane treatment should be initiated under the supervision of a physician experienced in the 
treatment of metabolic disorders. </p>
<p>Your doctor will evaluate your individual responsiveness to carglumic acid before initiating any long 
term treatment. 
The dose should be individually adjusted in order to maintain normal ammonia plasma levels. </p>
<p>Your doctor may prescribe supplemental arginine or restrict your protein intake. </p>
<p>In order to follow-up your condition and your treatment, your doctor may examine your liver, your 
kidneys, your heart and your blood on a regular basis. </p>
<p>Other medicines and Ucedane 
Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. </p>
<p>Ucedane with food and drink 
Ucedane must be taken orally before meals or feedings. 
The tablets must be dispersed in a minimum of 5 to 10 mL of water and taken immediately.  </p>
<p>Pregnancy and Breast-feeding 
The effects of Ucedane on pregnancy and the unborn child are not known.<br />
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine. </p>
<p>The excretion of carglumic acid into breast milk has not been studied in women. Nevertheless, as 
carglumic acid has been shown to be present in the milk of lactating rats with potential toxic effects 
for their fed pups, you should not breast-feed your baby if you are taking Ucedane. </p>
<p>Driving and using machines 
Effects on the ability to drive and use machines are not known. </p>
<p>Ucedane contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per maximum daily dose that is to 
say essentially  sodium-free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take ucedane"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take ucedane"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or 
pharmacist if you are not sure. </p>
<p>The usual dose: 
The initial daily dose is usually 100 mg per kilogram of body weight, up to a maximum of 250 mg 
per kilogram of body weight (for example, if you weight 10 kg, you should take 1 g per day, or 5 
tablets). For patients suffering from N-acetylglutamate synthase deficiency, in the long term, the 
daily dose usually ranges from 10 mg to 100 mg per kilogram of body weight.  </p>
<p>Your doctor will determine the dose suitable to you in order to maintain normal ammonia levels in 
your blood. </p>
<p>Ucedane should ONLY be administered by mouth or via a feeding tube into the stomach (using a 
syringe, if necessary). </p>
<p>When the patient is in hyperammonaemic coma, Ucedane is administered by fast push through a 
syringe via the tube set up and used to feed you. </p>
<p>Tell your doctor in case you are suffering from renal impairement. Your daily dose should be 
reduced. </p>
<p>If you take more Ucedane than you should 
Ask your doctor or pharmacist for advice. </p>
<p>If you forget to take Ucedane 
Do not take a double dose to make up for forgotten doses. </p>
<p>If you stop taking Ucedane 
Do not stop Ucedane without informing your doctor.  </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>The following side effects were reported as follows: very common (may affect more than 1 in people), common (may affect up to 1 in 10 people), uncommon (may affect up to 1 in 100 people), 
rare (may affect up to 1 in 1,000 people), very rare (may affect up to 1 in 10,000 people) and not 
known (frequency cannot be estimated from the available data). </p>
<ul>
<li>Common: increased sweating </li>
<li>Uncommon: bradycardia (decreased frequency of the heart), diarrhoea, fever, increased 
transaminases, vomiting </li>
<li>Not known: rash </li>
</ul>
<p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please 
tell your doctor or pharmacist. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or, pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety 
of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store ucedane"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store ucedane"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the blister and carton after EXP. 
The expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions.<br />
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how 
to throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Ucedane contains 
- The active substance is carglumic acid. Each tablet contains 200 mg of carglumic acid. 
- The other ingredients are microcrystalline cellulose, colloidal anhydrous silica, 
sodium stearyl fumarate (see section 2  Ucedane contains sodium ), mannitol, 
copovidone K28, crospovidone type B. </p>
<p>What Ucedane looks like and contents of the pack 
Ucedane dispersible tablets are rod-shaped, white, and biconvex with three score lines on both sides 
and engraving  L/L/L/L  on one side. 
Approximate tablet dimensions are 17 mm in length and 6 mm in width. 
The tablet can be divided into four equal doses. 
The tablets are presented in aluminium/aluminium blister packed in a carton. 
Pack size of 12 or 60 dispersible tablets. 
Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder<br />
Eurocept International BV 
Trapgans 5 
1244 RL Ankeveen 
The Netherlands </p>
<p>Manufacturer 
Eurocept International BV 
Trapgans 5 
1244 RL Ankeveen 
The Netherlands </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Lucane Pharma 
T l/Tel: + 33 153 868 info@lucanepharma.com </p>
<p>Lietuva<br />
FrostPharma AB 
Tel: +46 775 86 80 info@frostpharma.com </p>
<p>Lucane Pharma 
Te .: + 33 153 868 info@lucanepharma.com </p>
<p>Luxembourg/Luxemburg 
Lucane Pharma 
T l/Tel: + 33 153 868 info@lucanepharma.com 
 esk  republika 
Lucane Pharma 
T l/Tel: + 33 153 868 info@lucanepharma.com </p>
<p>Magyarorsz g 
Lucane Pharma 
Tel: + 33 153 868 info@lucanepharma.com 
Danmark 
FrostPharma AB 
Tlf: +45 808 20 info@frostpharma.com </p>
<p>Malta 
Lucane Pharma 
Tel: + 33 153 868 info@lucanepharma.com </p>
<p>Deutschland 
Lucane Pharma 
Tel: + 33 153 868 info@lucanepharma.com </p>
<p>Nederland 
Eurocept International BV 
Tel: +31 35 528 39 info@euroceptpharma.com 
Eesti 
FrostPharma AB 
Tel: +46 775 86 80 info@frostpharma.com </p>
<p>Norge 
FrostPharma AB 
Tlf: +47 815 03 info@frostpharma.com </p>
<p>Lucane Pharma 
 : + 33 153 868  sterreich 
Lucane Pharma 
Tel: + 33 153 868 info@lucanepharma.com </p>
<p>info@lucanepharma.com 
Espa a 
Lucane Pharma 
Tel: + 33 153 868 info@lucanepharma.com </p>
<p>Polska 
Lucane Pharma 
Tel: + 33 153 868 info@lucanepharma.com 
France 
Lucane Pharma 
T l: + 33 153 868 info@lucanepharma.com </p>
<p>Portugal 
Lucane Pharma 
Tel: + 33 153 868 info@lucanepharma.com 
Hrvatska 
Lucane Pharma 
Tel: + 33 153 868 info@lucanepharma.com </p>
<p>Rom nia 
Lucane Pharma 
Tel: + 33 153 868 info@lucanepharma.com </p>
<p>Ireland 
Lucane Pharma 
Tel: + 33 153 868 info@lucanepharma.com </p>
<p>Slovenija 
Lucane Pharma 
Tel: + 33 153 868 info@lucanepharma.com 
 sland 
FrostPharma AB 
S mi: +46 775 86 80 info@frostpharma.com </p>
<p>Slovensk  republika 
Lucane Pharma 
Tel: + 33 153 868 info@lucanepharma.com 
Italia 
Lucane Pharma 
Tel: + 33 153 868 info@lucanepharma.com 
Suomi/Finland 
FrostPharma AB 
Puh/Tel: +35 875 32 51 info@frostpharma.com </p>
<p>Lucane Pharma 
 : + 33 153 868 info@lucanepharma.com </p>
<p>Sverige 
FrostPharma AB<br />
Tel: +46 775 86 80 info@frostpharma.com </p>
<p>Latvija 
FrostPharma AB 
Tel: +46 775 86 80 info@frostpharma.com 
United Kingdom (Northern Ireland) 
Lucane Pharma 
Tel: + 33 153 868 info@lucanepharma.com </p>
<p>This leaflet was last revised in  </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      

